This nonrandomized prospective study consisted of 20 consecutive patients with IFTMH. All surgical procedures took place at Mansoura Ophthalmic Center between January 2014 and December 2014.
Inclusion criteria were patients who had successfully undergone PPV with ILM peeling for an IFTMH (larger than 400 μm), with postoperative follow-up period of at least 6 months. Patients were excluded if they had high myopia (≥6 D or axial length [AL] ≥26 mm), eyes with postoperative complications, such as reopening of the MH, a history of ocular surgeries or trauma, and patients with ocular or systemic disorders which could affect the inner RNFL and GC-IPL (e.g., glaucoma, age-related macular degeneration, or optic nerve diseases). Patients with optical media opacity that significantly disturbed OCT image acquisition (e.g., significant postoperative cataract or posterior capsular opacity in either eye) were also excluded. The study protocol was approved by the Institutional Review Board of Mansoura Ophthalmic Center and adhered to the tenets of the Declaration of Helsinki. Written informed consent was obtained from all patients after the nature of the study was explained to them in clear understandable words.
All patients underwent comprehensive ophthalmologic examinations including measurement of best-corrected visual acuity (BCVA), IOP by Goldmann applanation tonometry, noncycloplegic refraction (autorefractor KR-8900; Topcon Corporation, Tokyo, Japan), AL (Nidek Echoscan-2000, Birmingham, UK), slit-lamp biomicroscopy, indirect fundus examination, and SD-OCT (2000, Topcon Corp.). Best-corrected visual acuity measurements were made using a Landolt chart and were converted to units of logarithms of the minimum angle of resolution (logMAR) for statistical analyses. Additionally, refraction data were converted to spherical equivalent for analysis.